Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy. In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for hunger and reward in patients treated with tirzepatide. A recent study has ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone ...

Achieving these outcomes with a second obesity medication may indicate a broader efficacy trend for pairing these ... hormone therapy enhances the effectiveness of tirzepatide for weight loss in ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy. In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist ...

In key secondary endpoints, Zepbound was superior across all weight reduction targets with 64.6% of participants treated with Zepbound achieving at least 15.0% weight loss compared to 40.1% on Wegovy.